TrialCompass TCL
Back to results
Phase 1, Phase 2RecruitingPriority 3 · Moderate priorityNCT07502768

Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This Phase 1, Phase 2 trial is comparing Tislelizumab and Zeprumetostat against other options for people whose NK/T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Tislelizumab (DRUG): Tislelizumab 200 mg administered intravenously on day 1 of each 21-day cycle. | Zeprumetostat (DRUG): Zeprumetostat (SHR2554), an oral EZH2 inhibitor, administered twice daily. In phase Ib, dose levels are 300 mg BID and 350 mg BID. In phase II, zeprumetostat is administered at the recommended phase II dose selected from phase Ib.

Drugs / treatments
Tislelizumab, Zeprumetostat
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma

NCT07502768

Phase: Phase 1, Phase 2 | Status: Recruiting | Priority: Medium

Plain-language summary

This Phase 1, Phase 2 trial is comparing Tislelizumab and Zeprumetostat against other options for people whose NK/T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

Tislelizumab (DRUG): Tislelizumab 200 mg administered intravenously on day 1 of each 21-day cycle. | Zeprumetostat (DRUG): Zeprumetostat (SHR2554), an oral EZH2 inhibitor, administered twice daily. In phase Ib, dose levels are 300 mg BID and 350 mg BID. In phase II, zeprumetostat is administered at the recommended phase II dose selected from phase Ib.

Drugs / treatments: Tislelizumab, Zeprumetostat

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Randomized, open-label

Enrollment target: 107 patients

Primary endpoint: Recommended Phase II Dose (RP2D) of zeprumetostat in combination with tislelizumab; Objective Response Rate (ORR) at Week 12

Ages: 18 Years to —

Start date: 2026-04-30 | Est. completion: 2028-12-30

Locations

0 US sites · 1 total

Contact

Rong Tao, MD & PhD | hkutao@hotmail.com | 008621-64175590

Sponsor: Rong Tao (OTHER)

Tags

ENKTL · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07502768

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.